SCHEMBL9897215

SCHEMBL9897215

C#Cc1cccc(Nc2ncnc3[nH]cc(CN4CCC(=O)CC4)c23)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.49
ERBB2 P04626 1/20 0.49
LRRK2 Q5S007 1/20 0.44
BRAF P15056 1/20 0.42
TNNI3K Q59H18 1/20 0.42
KDR P35968 1/20 0.42
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
GAK O14976 1/20 0.41
RIPK2 O43353 1/20 0.41
BUB1 O43683 1/20 0.41
STK10 O94804 1/20 0.41
CARS1 P49589 1/20 0.41
MAP3K1 Q13233 1/20 0.41
PIP4K2C Q8TBX8 1/20 0.41
SLK Q9H2G2 1/20 0.41
FBP1 P09467 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904053 0.87 EGFR (0.65) EGFRERBB2KDR
SCHEMBL9928288 0.86 EGFR (0.55) EGFRERBB2LRRK2BRAFTNNI3K
SCHEMBL9928297 0.86 EGFR (0.49) EGFRERBB2LRRK2BRAFTNNI3K
SCHEMBL9928320 0.85 EGFR (0.48) EGFRERBB2LRRK2BRAFTNNI3K
SCHEMBL9898681 0.85 EGFR (0.53) EGFRERBB2LRRK2BRAFTNNI3K
SCHEMBL9897735 0.84 EGFR (0.49) EGFRERBB2LRRK2BRAFTNNI3K
SCHEMBL9900019 0.83 EGFR (0.52) EGFRERBB2BRAFTNNI3KKDR
SCHEMBL9898368 0.79 AAK1 (0.48) EGFRERBB2LRRK2
SCHEMBL9895699 0.79 EGFR (0.41) EGFRERBB2BRAFTNNI3KAURKA
SCHEMBL7016150 0.75 BRAF (0.58) EGFRERBB2LRRK2BRAFTNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2511276-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE Ube Industries, Ltd. (JP) 2012-10-17 EP disclosed
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2012-06-14 US disclosed
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2012-06-14 US disclosed
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE ERBB2, EGFR, FGFR1 EGFR 2/4885ERBB2 1/4885LRRK2 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.